Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Wells Fargo & Co — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.39 (market cap $2.27B), while Wells Fargo & Co trades at $82.79 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 109.3× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Wells Fargo & Co pays a 2.44% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SLS | WFC | |
|---|---|---|
Market Cap | $2.27B | $248.06B |
Volume | 4,179,659 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $15.46 | $96.40 |
52-Week Low | $1.39 | $73.42 |
Enterprise Value | $2.14B | $503.91B |
Typical Hold Time | — | 87 Days |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wells Fargo (WFC) trades at $80.26, down 1.53% today, with a bearish technical signal despite recent earnings beat in Q2 2026. The company shows strong fundamentals with a P/E of 11.92, net income margin of 25.97%, and a recent credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01). Revenue growth is steady, reaching $83.70B in 2025, with a consensus price target of $99.13 suggesting upside potential.
The stock presents a value opportunity with attractive valuation metrics and improving profitability, but faces risks from volatile cash flows and regulatory changes in bank stress tests. Analyst sentiment is mixed with 46.66% buy ratings, while technical indicators signal near-term caution. Upside hinges on Q3 2026 earnings meeting expectations of $1.85 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
